Literature DB >> 6453555

Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

W K Bolton, W M Scheld, D A Spyker, T L Overby, M A Sande.   

Abstract

We have examined the pharmacokinetics of moxalactam (LY127935) in 36 subjects with various degrees of renal dysfunction. Creatinine clearance (Ccr)/1.73 m2 ranged from zero to 135.8 ml/min. After a 1-g administration of moxalactam intravenously, the volume of distribution was 20.6 /+- 9.5 liters (0.28 liter/kg), and the mean half-life ranged from 3.1 h for subjects with Ccr greater than 65 ml/min to 19.3 h for subjects with Ccr less than 10 ml/min. The moxalactam clearance was closely correlated to Ccr (r = 0.93, P less than 0.0001) and excretion of antibiotic was 73.6 +/- 13% in normal subjects. Renal clearance accounted for 90% of moxalactam clearance in the normal subjects. A dosage schedule for administering moxalactam to patients with various degrees of renal dysfunction is provided.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6453555      PMCID: PMC352992          DOI: 10.1128/AAC.18.6.933

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacology of cefazolin in patients with normal and abnormal renal function.

Authors:  M E Levison; S P Levison; K Ries; D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

2.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

3.  Pharmacology of cefazolin and other cephalosporins in patients with renal insufficiency.

Authors:  W A Craig; P G Welling; T C Jackson; C M Kunin
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Response model analysis for cross-fostering studies: prenatal versus postnatal effects on offspring exposed to methylmercury dicyandiamide.

Authors:  D A Spyker; J M Spyker
Journal:  Toxicol Appl Pharmacol       Date:  1977-06       Impact factor: 4.219

5.  Pharmacokinetics of cefazolin in patients with renal failure; special reference to hemodialysis.

Authors:  J M Brogard; M Pinget; C Brandt; J Lavillaureix
Journal:  J Clin Pharmacol       Date:  1977-04       Impact factor: 3.126

6.  Gentamicin dosage.

Authors: 
Journal:  Ann Intern Med       Date:  1977-03       Impact factor: 25.391

7.  Stature and lean body mass.

Authors:  G B Forbes
Journal:  Am J Clin Nutr       Date:  1974-06       Impact factor: 7.045

8.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

9.  Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function.

Authors:  D A Spyker; B L Thomas; M A Sande; W K Bolton
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

10.  Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.

Authors:  D A Spyker; R J Rugloski; R L Vann; W M O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

View more
  17 in total

Review 1.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

2.  Effect of probenecid on the pharmacokinetics of moxalactam.

Authors:  K A DeSante; K S Israel; G L Brier; J D Wolny; B L Hatcher
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

3.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

4.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

Review 5.  The third generation cephalosporins.

Authors:  B Farber; R C Moellering
Journal:  Bull N Y Acad Med       Date:  1982-11

6.  Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

Authors:  T E Jones; R W Milne; Y Mudaliar; L N Sansom
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

7.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.

Authors:  D J Swanson; D P Reitberg; I L Smith; P B Wels; J J Schentag
Journal:  J Pharmacokinet Biopharm       Date:  1983-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.